Delivery Order SPE2DR25D3005-SPE2DR26FP7QU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Xeomin 200 Unit Vials, with a ceiling value of $23,553.20 and an ultimate completion date of December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $14,979.80 firm fixed price delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Xeomin 200 unit vials, with completion scheduled for December 26, 2025. This non-set-aside competitive award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical support vehicle running through December 2026. The delivery order will be fulfilled from...
- The Defense Logistics Agency awarded a $19,569.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 3, 2025, for the supply of Xeomin 100 Unit Vials, with completion required by January 27, 2025. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $69,283.76 delivery order to AmerisourceBergen Drug Corp for the supply of Xeomin 200 unit vials, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,766.46 for 100-unit vials of Xeomin on December 3, 2025, with completion scheduled for December 24, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $11,733.54 to AmerisourceBergen Drug Corp for the supply of Xeomin 100 Unit Vials, with a completion date of November 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor to the federal government,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xeomin 100 Unit Vials with a ceiling value of $35,535.50 under a firm fixed-price contract. This non-set-aside award is scheduled for completion by October 8, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a competitively awarded procurement action sourced through the company's...
- The Defense Logistics Agency awarded a $49,461.72 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin on December 10, 2025, with a completion date of January 2, 2026. This firm fixed-price contract utilizes a competitive, non-set-aside procurement process and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Xeomin 100 Unit Vials, valued at $5,888.20. This is a firm fixed-price delivery order with a completion date of December 31, 2025, and represents a non-competitive set-aside award. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP7QUDelivery Order
The Defense Logistics Agency awarded a $14,720.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Xeomin 100 Unit Vials, with an ultimate completion date of December 23, 2025. This competitive award carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order under its broader relationship with DLA as a critical vendor for federal medical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply pharmaceutical products and medical supplies to military healthcare programs worldwide. The Xoemin order supports the Defense Health Agency and other government healthcare systems requiring specialized pharmaceutical products across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.7k | 12/1/25 |